UroGen Pharma Ltd. (URGN) P/E Ratio History
Deep ValueTrading at -11.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2017–2017
Loading P/E history...
P/E Ratio Analysis
As of October 10, 2026, UroGen Pharma Ltd. (URGN) trades at a price-to-earnings ratio of -11.5x, with a stock price of $36.83 and trailing twelve-month earnings per share of $-1.94.
The current P/E is 106% below its 5-year average of 177.9x. Over the past five years, URGN's P/E has ranged from a low of 177.9x to a high of 177.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, URGN trades at a 149% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 164.5x.
Relative to the broader market, URGN trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our URGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
URGN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
URGN P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 32.2 | 4.21 | +1883%Best | |
| $8B | 20.0Lowest | - | +1747% | |
| $2B | 22.3 | - | +419% | |
| $629B | 23.7 | 1.56Best | +91% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
URGN Historical P/E Data (2017–2017)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2017 Q3 | Sep 30 2017 | $31.52 | $0.18 | 177.9x | +0% |
Average P/E for displayed period: 177.9x
URGN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
URGN — Frequently Asked Questions
Quick answers to the most common questions about buying URGN stock.
What is URGN's P/E ratio?
UroGen Pharma Ltd. (URGN) trailing twelve-month P/E ratio is -11.5x, based on TTM diluted EPS of $-1.94. The 5-year average P/E is 177.9x and the historical range spans 177.9x to 177.9x.
Is URGN stock overvalued or undervalued?
URGN trades at -11.5x P/E, below its 5-year average of 177.9x. At the 0th percentile of its historical range (177.9x–177.9x), the stock is priced at a discount to its own history.
Is URGN stock expensive?
No, URGN is not expensive on a historical basis. The current P/E of -11.5x is below the 5-year average of 177.9x and sits at the 0th percentile of its valuation range.
What is URGN's historical P/E range?
Over the past 5 years, URGN's P/E ratio has ranged from 177.9x to 177.9x, with a median of 177.9x and an average of 177.9x. The current P/E of -11.5x places the stock at the 0th percentile of this range. Full historical data spans 2017–2017.
How does URGN's P/E compare to the S&P 500?
URGN trades at -11.5x P/E versus the S&P 500 median of 25.3x. The 145% discount to the market suggests lower growth expectations or perceived higher risk.
How does URGN's valuation compare to Healthcare peers?
UroGen Pharma Ltd. P/E of -11.5x compares to the Healthcare sector median of 23.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is URGN's PEG ratio?
URGN PEG ratio is N/A, based on a P/E of -11.5x and EPS growth of -7.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is URGN's earnings yield?
URGN earnings yield is N/A, the inverse of its -11.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.